Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALMS Alumis Inc.

Pre-Mkt 02-26 06:48:28 EST

29.39

+1.31

+4.67%

盘前29.39

+0.000.00%

04:59 EST

High30.03	Low28.64	Vol1.09M
Open28.87	D1 Closing28.08	Amplitude4.97%
Mkt Cap3.59B	Tradable Cap2.28B	Total Shares122.00M
T/O32.26M	T/O Rate1.41%	Tradable Shares77.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":29.39,"timestamp":1772053200000,"preClose":28.08,"halted":0,"volume":1091602,"hourTrading":{"tag":"盘前","latestPrice":29.39,"preClose":29.39,"latestTime":"04:59 EST","volume":7,"amount":205.73000000000002,"timestamp":1772099993812,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.046652421652421734,"floatShares":77486300,"shares":122000000,"eps":-3.8545,"marketStatus":"Pre-Mkt","change":1.31,"latestTime":"02-26 06:48:28 EST","open":28.865,"high":30.03,"low":28.635,"amount":32256954.809812,"amplitude":0.049679,"askPrice":30.59,"askSize":65,"bidPrice":28.01,"bidSize":65,"shortable":3,"etf":0,"ttmEps":-3.8545,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":29.39,"preHourTrading":{"tag":"盘前","latestPrice":29.39,"preClose":29.39,"latestTime":"04:59 EST","volume":7,"amount":205.73000000000002,"timestamp":1772099993812,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":28.81,"preClose":29.39,"latestTime":"19:55 EST","volume":33724,"amount":990704.0743,"timestamp":1772067340691,"change":-0.58,"changeRate":-0.019735,"amplitude":0.019735},"volumeRatio":0.7108437075330998,"impliedVol":0.9611,"impliedVolPercentile":0.2624},"requestUrl":"/m/hq/s/ALMS/wiki","defaultTab":"wiki","newsList":[{"id":"2614082899","title":"Alumis Inc : Stifel Initiates Coverage With Buy Rating; Price Target $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082899?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:53","pubTimestamp":1772024016,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2614817150","title":"Stifel Initiates Alumis at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2614817150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614817150?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:20","pubTimestamp":1772022058,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of buy and mean price target of $38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and resea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","SF"],"gpt_icon":0},{"id":"2614213703","title":"U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP","url":"https://stock-news.laohu8.com/highlight/detail?id=2614213703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614213703?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:20","pubTimestamp":1772004027,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HPFeb 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chevron, GoDaddy and HP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDD","BMRN","BWIN","BAM","GLW","AMT","AUGO","AMYY","BEAM","BIOA","AFL","AMUU","CAVA","AMDU","AMD","ABBV","CECO","CYTK","CVX","BCC","CZR","CRL","CAT","AMDL","AXON","CRCD","CRCL","CRBG","ALMS","ICRC","BMY","BBIO","CDNA","BOW","CSGP","ATRO","CEG","AU","CCUP","AMDY","CEGX","SAM","ANGX","AVB","ADUS","CORT","BURL","AMDG","IPSC","CRCG"],"gpt_icon":0},{"id":"2609082593","title":"Alumis to Participate in Upcoming February Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2609082593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609082593?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:05","pubTimestamp":1770296700,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb.  05, 2026  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-media","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232969/0/en/Alumis-to-Participate-in-Upcoming-February-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2605104192","title":"Alumis Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605104192","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605104192?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:35","pubTimestamp":1768998900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 07:35 ET (12:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2605104383","title":"Chardan Initiates Alumis at Buy With $37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605104383","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605104383?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:20","pubTimestamp":1768998055,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of buy and mean price target of $37.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS"],"gpt_icon":0},{"id":"2605174452","title":"Alumis Inc. (ALMS) Receives a Buy from Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605174452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605174452?lang=en_us&edition=fundamental","pubTime":"2026-01-21 16:35","pubTimestamp":1768984558,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst initiated coverage with a Buy rating on Alumis Inc. today and set a price target of $37.00. In addition to Chardan Capital,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-buy-from-chardan-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-buy-from-chardan-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2604104679","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2604104679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604104679?lang=en_us&edition=fundamental","pubTime":"2026-01-17 09:39","pubTimestamp":1768613940,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Jan. 8 through Jan. 14, 2026. Source: VerityData. Monte Rosa Therapeutics Versant Venture Capital VI reduced its stake in the biotechnology company to 3,250,069 shares. Versant Venture Capital did so through the sale of 597,931 Monte Rosa Therapeutics shares from Nov. 19, 2025, through Jan. 7, 2026, at per share prices ranging from $14.25 to $23.33, and also completed pro rata distributions of 500,030 shares on Dec. 4 and 560,092 shares on Jan. 8. Following the latest activity, Versant Venture Capital continues to own a 4.99% stake in Monte Rosa Therapeutics' outstanding stock, placing Ve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4539","GLUE","BK4585","ASTE","BK4588","VTOL","BK4179","ALMS","BK4139","STAA","BK4149","BK4007","BK4198"],"gpt_icon":0},{"id":"2603043116","title":"Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603043116","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603043116?lang=en_us&edition=fundamental","pubTime":"2026-01-15 16:32","pubTimestamp":1768465924,"startTime":"0","endTime":"0","summary":"Earlier in January 2026, Alumis Inc. reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis and subsequently completed a US$300.05 million follow-on common stock offering at US$17.00 per share.\nA key angle for investors is how envudeucitinib’s differentiated clinical profile and “pipeline-in-a-pill” potential, including possible applications in systemic lupus erythematosus, could influence Alumis’s...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/alumis-alms-is-up-358-after-psoriasis-data-and-300m-raise-ha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/alumis-alms-is-up-358-after-psoriasis-data-and-300m-raise-ha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2603645362","title":"Alumis rises 10.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603645362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603645362?lang=en_us&edition=fundamental","pubTime":"2026-01-15 01:07","pubTimestamp":1768410456,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) is up 10.2%, or $2.26 to $24.37. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-rises-10-2-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-rises-10-2-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2603650863","title":"Insider Makes Bold Multimillion-Dollar Bet on Alumis Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603650863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603650863?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:01","pubTimestamp":1768356112,"startTime":"0","endTime":"0","summary":"New insider activity at Alumis Inc. ( ($ALMS) ) has taken place on January 13, 2026. Director Srinivas Akkaraju has made a significant insider purc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-multimillion-dollar-bet-on-alumis-inc-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-multimillion-dollar-bet-on-alumis-inc-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"1139751814","title":"Form 4 | Alumis Inc. Director Akkaraju Srinivas acquired 588,235 shares.","url":"https://stock-news.laohu8.com/highlight/detail?id=1139751814","media":"Filings Track","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139751814?lang=en_us&edition=fundamental","pubTime":"2026-01-14 07:25","pubTimestamp":1768346733,"startTime":"0","endTime":"0","summary":"Akkaraju Srinivas, Director of Alumis Inc., acquired 588,235 shares of common stock on January 9, 2026, at a price of $17 per share via Samsara Opportunity Fund, L.P. This transaction indicates...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Form 4 | Alumis Inc. Director Akkaraju Srinivas acquired 588,235 shares.","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":1},{"id":"1105451311","title":"ALUMIS INC. Director Foresite Capital Management VI LLC purchased 411,764 Shares.","url":"https://stock-news.laohu8.com/highlight/detail?id=1105451311","media":"Filings Track","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105451311?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:20","pubTimestamp":1768274427,"startTime":"0","endTime":"0","summary":"ALUMIS INC. Director Foresite Capital Management VI LLC conducted 2 purchases on January 8, 2026, totaling 411,764 shares at a price of $17 per share. The increase in holdings is usually seen as a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"1100853925","title":"ALUMIS Inc. Director James B. Tananbaum purchased 411,764 Shares.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100853925","media":"Filings Track","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100853925?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:12","pubTimestamp":1768273933,"startTime":"0","endTime":"0","summary":"ALUMIS Inc. (ALMS) Director James B. Tananbaum purchased 411,764 shares of common stock on January 8, 2026, at a price of $17 per share. After the purchase, James B. Tananbaum indirectly holds...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":1},{"id":"2603576414","title":"Foresite Labs Reports Acquisition of Alumis Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576414","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576414?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:59","pubTimestamp":1768273181,"startTime":"0","endTime":"0","summary":"Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC reported the acquisition of common shares of Alumis Inc. , according to a recent SEC filing. Other reporting beneficial owners were also listed in the filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL6Kbzw0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":1},{"id":"2603576172","title":"Director and 10% Owner James B. Tananbaum Acquires Common Shares of Alumis Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576172","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576172?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:58","pubTimestamp":1768273138,"startTime":"0","endTime":"0","summary":"James B. Tananbaum, a Director and 10% Owner, reported the acquisition of common shares of Alumis Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3d9MB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director and 10% Owner James B. Tananbaum Acquires Common Shares of Alumis Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":1},{"id":"2602510564","title":"Alumis Inc. Showcases Breakthrough TYK2 Inhibitor Results for Psoriasis and Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510564","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510564?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222884,"startTime":"0","endTime":"0","summary":"Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Techno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbMMvz0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":1},{"id":"2602309003","title":"Alumis Closes Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602309003","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602309003?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:11","pubTimestamp":1767993098,"startTime":"0","endTime":"0","summary":"Alumis  said late Friday it closed an upsized public offering of nearly 20.3 million common shares at $17 apiece for gross proceeds of $345.1 million.The offering comprised over 2.6 million shares issued upon the full exercise of an overallotment option by underwriters, according to a statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2602930974","title":"Press Release: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602930974","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602930974?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:05","pubTimestamp":1767992700,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $345.1 million. All of the shares in the offering were sold by Alumis.Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities acted as joint book-running managers for the offering. Baird and Oppenheimer & Co. acted as co-lead managers for the offering.Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","LU1791710582.SGD","LU1201861249.SGD","LU0310800379.SGD","LU2461242641.AUD","LU0971096721.USD","LU1989772923.USD","LU0314106906.USD","LU0314104364.USD","IE00B7SZLL34.SGD","LU0211328371.USD","LU1069347547.HKD","LU0052756011.USD","IE00B19Z3B42.SGD","LU1244550577.SGD","BK4588","LU0320765646.SGD","LU0942090050.USD","LU2361044949.HKD","LU0417517546.SGD","LU0098860793.USD","BK4007","LU2357305700.SGD","BK4127","LU1894683348.USD","LU2089283258.USD","LU0267386448.USD","LU1363072403.SGD","ALMS","LU1244550221.USD","LU1720051017.SGD","LU1732799900.SGD","LU0477156953.USD","LU2361044865.SGD","LU1506573853.SGD","LU0310800965.SGD","LU0149725797.USD","BK4534","LU0006306889.USD","LU0320765489.SGD","LU0106261372.USD","LU0048573561.USD","LU1791807156.HKD","LU0868494617.USD","LU0128525929.USD","LU2023251221.USD","LU2133065610.SGD","LU0980610538.SGD","LU0795875169.SGD","LU0289960550.SGD"],"gpt_icon":1},{"id":"2602378852","title":"Alumis Price Target Raised to $40.00/Share From $20.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602378852?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:50","pubTimestamp":1767959400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 06:50 ET (11:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":0.0683},{"period":"1month","weight":0.1171},{"period":"3month","weight":2.8469},{"period":"6month","weight":5.3341},{"period":"1year","weight":5.0598},{"period":"ytd","weight":2.0113}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}